Trials / Completed
CompletedNCT02981836
A Blind, Randomized and Controlled Study of Live Attenuated Varicella Vaccines
A Blind, Randomized and Controlled Clinical Trial to Evaluate the Protective Effect, Safety and Immunogenicity of Live Attenuated Varicella Vaccines for Healthy Children
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 5,997 (actual)
- Sponsor
- Sinovac (Dalian) Vaccine Technology Co., Ltd. · Industry
- Sex
- All
- Age
- 1 Year – 12 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this study is to evaluate the protective effect, safety and immunogenicity of a live attenuated varicella vaccine in healthy children.
Detailed description
This study is a randomized, blind, controlled phase III clinical trial. The purpose of this study is to evaluate the protective effect, safety and immunogenicity of a live attenuated varicella vaccine manufactured by Sinovac (Dalian) Vaccine Technology Co., Ltd. The control is diluent of lyophilized vaccine manufactured by Sinovac (Dalian) Vaccine Technology Co., Ltd. All participants are healthy, and will be randomly assigned into experimental group or control group in the ratio 1:1.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Investigational live attenuated varicella vaccine | The investigational vaccine was manufactured by Sinovac (Dalian) Vaccine Technology Co., Ltd. |
| BIOLOGICAL | diluent of lyophilized vaccine | The diluent of lyophilized vaccine was manufactured by Sinovac (Dalian) Vaccine Technology Co., Ltd. |
Timeline
- Start date
- 2016-08-01
- Primary completion
- 2017-06-01
- Completion
- 2017-09-01
- First posted
- 2016-12-05
- Last updated
- 2017-10-26
Locations
2 sites across 1 country: China
Source: ClinicalTrials.gov record NCT02981836. Inclusion in this directory is not an endorsement.